NCT00410605 · REGISTRY CONDITION SEARCH

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2017-09-01

This phase II trial is studying how well giving bevacizumab together with lenalidomide and dexamethasone works in treating patients with relapsed or refractory stage II or stage III multiple myeloma. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab and lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Dexamethasone may stimulate the immune system in different ways and stop cancer cells from growing. Giving bevacizumab together with lenalidomide and dexamethasone may kill more cancer cells.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bevacizumab and Lenalidomide

→

outcome · POSTED

Progression Free Survival (Time to Progression)

→

outcome · POSTED

Toxicity and Tolerability of the Bevacizumab and Lenalidomide Combination

→

outcome · POSTED

Effect of Bev/Rev on Markers of Myeloma Activity in Myeloma Cells and Stromal Cells at Baseline

→

outcome · POSTED

Local Cytokine Milieu Using Tissue Micro Arrays of Bone Marrow Biopsy Specimens

→

outcome · POSTED

Effect of Bev/Rev on Markers of Myeloma Activity in Myeloma Cells and Stromal Cells at 3 Months Post-baseline

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically or cytologically confirmed symptomatic multiple myeloma: * Stage II or III disease * Relapsed or refractory disease after \>= 2 courses of prior chemotherapy * Measurable levels of monoclonal protein (M protein) \> 1.0 g/dL by serum protein electrophoresis OR \> 200 mg of monoclonal light chain by 24-hour urine protein electrophoresis * Measurable bone disease, defined as \>= 1 unidimensionally measurable lesion (longest diameter to be recorded) \>= 20 mm with conventional techniques OR \>= 10 mm with spiral CT scan (for patients with lytic bone disease) * No known brain metastases * ECOG performance status (PS) 0-2 OR Karnofsky PS 70-100% * Patients with PS of 3 are eligible if it is due to pain that is likely to improve with treatment * Life expectancy \> 6 months * No known HIV positivity * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * No active infections requiring oral or intravenous antibiotics within the past week * No proteinuria (i.e., albuminuria) \> 1,000 mg/24 hours unless related to the diagnosis of multiple myeloma * Patients with light chain (i.e., "Bence-Jones") proteinuria are still eligible if the non-light chain component of protein is \< 1,000 mg/24 hours * No serious nonhealing wound or ulcer * No blood pressure \> 150/90 mm Hg (even with medication) * No significant traumatic injury within the past 28 days * No clinically significant peripheral vascular disease * No evidence of bleeding diathesis or coagulopathy * No unstable angina or myocardial infarction within the past 6 months * No stroke within the past 6 months * No New York Heart Association class III or IV heart failure * No secondary malignancy within the past 2 years except squamous cell or basal cell carcinoma of the skin or carcinoma in situ of the cervix * Hemoglobin \> 9 g/dL (may be supported by transfusion or growth factors) * WBC \>= 2,000/mm\^3 * Absolute neutrophil count \>= 1,000/mm\^3 * Platelet count \>= 75,000/mm\^3 * Bilirubin =\< 2.5 mg/dL * At least 4 weeks since prior chemotherapy or radiotherapy and recovered * More than 7 days since prior minor surgical procedures, fine-needle aspirations, or core biopsies: More than 24 hours since prior bone marrow biopsy or central veinous access placement * More than 28 days since prior major surgical procedure or open biopsy * At least 4 weeks since prior and no concurrent participation in another experimental drug study * Prior autologous peripheral blood stem cell transplantation allowed * No prior lenalidomide * Concurrent full-dose anticoagulants allowed provided all of the following criteria are met: * No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) * No thrombocytopenia requiring transfusion * Platelet count \> 75,000/mm3 * INR 2-3 and stable * No concurrent major surgery * No concurrent sargramostim (GM-CSF) * No other concurrent investigational agents * No other concurrent anticancer agents or therapies * AST and ALT =\< 5 times upper limit of normal * Creatinine \< 2.5 mg/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use 2 methods of effective contraception 4 weeks before, during, and 4 weeks after completion of study treatment * No history of allergic reactions attributed to compounds of similar chemical or biological composition to lenalidomide and/or bevacizumab or other agents used in the study
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
intervention Names
Biological: bevacizumab
Drug: lenalidomide
Drug: dexamethasone
label
Arm I
type
EXPERIMENTAL

interventions

arm Group Labels
Arm I
description
Given IV
name
bevacizumab
other Names
anti-VEGF humanized monoclonal antibody
anti-VEGF monoclonal antibody
Avastin
rhuMAb VEGF
type
BIOLOGICAL
arm Group Labels
Arm I
description
Given orally
name
lenalidomide
other Names
CC-5013
IMiD-1
Revlimid
type
DRUG
arm Group Labels
Arm I
description
Given orally
name
dexamethasone
other Names
Aeroseb-Dex
Decaderm
Decadron
DM
DXM
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 39
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Patient response to the treatment were determined by the definitions for complete response, partial response, marginal response, stable disease, and progressive disease outlined by IMBTR/ABMTR (Blade criteria). Responses were analyzed by descriptive statistics and summarized in tabular format (frequency tables). Furthermore, two-sided 95% confidence intervals for the proportions of subjects with a confirmed anti-tumor response were computed using the method proposed by Chang, which takes into account the multiplicity problem associated with the two-stage testing procedure. The objective response rate was estimated by using Whitehead's bias-adjustment approach.
measure
Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bevacizumab and Lenalidomide
time Frame
Up to 5 years
description
Patient response to the treatment were determined by the definitions for complete response, partial response, marginal response, stable disease, and progressive disease outlined by IMBTR/ABMTR (Blade criteria). Progression free survival was summarized using point estimates of the median time to progression and associated 95% confidence intervals. The data was presented graphically using Kaplan-Meier plots. Exploratory analysis, including multivariate Cox regression with demographic variables and markers of myeloma activity as covariates was performed.
measure
Progression Free Survival (Time to Progression)
time Frame
up to five years

secondary Outcomes

description
Adverse events/toxicities were collected during regular clinical visits. Confidence intervals for the estimate of the true number of patients suffereing from grade 3 or 4 toxicities per common terminology criteria were calculated using the Wilson interval. Ninety-five percent confidence intervals for the proportions of patients with complications (grade 3 or higher toxicities) were constructed.
measure
Toxicity and Tolerability of the Bevacizumab and Lenalidomide Combination
time Frame
Up to 5 years
description
A Wilconxon signed-rank test conducted to determine if biomarker levels differed between baseline levels and those after three full cycles of treatment for all patients.
measure
Effect of Bev/Rev on Markers of Myeloma Activity in Myeloma Cells and Stromal Cells at Baseline
time Frame
Baseline
measure
Local Cytokine Milieu Using Tissue Micro Arrays of Bone Marrow Biopsy Specimens
time Frame
Up to 5 years
description
A Wilconxon signed-rank test conducted to determine if biomarker levels differed between baseline levels and those after three full cycles of treatment for all patients.
measure
Effect of Bev/Rev on Markers of Myeloma Activity in Myeloma Cells and Stromal Cells at 3 Months Post-baseline
time Frame
Up to Course 4 Day 1 (3 Months Post-baseline)

Full study description

brief Summary: This phase II trial is studying how well giving bevacizumab together with lenalidomide and dexamethasone works in treating patients with relapsed or refractory stage II or stage III multiple myeloma. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab and lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Dexamethasone may stimulate the immune system in different ways and stop cancer cells from growing. Giving bevacizumab together with lenalidomide and dexamethasone may kill more cancer cells.
detailed Description: PRIMARY OBJECTIVES: I. Determine the overall response rate (complete response and partial response) in patients with relapsed or refractory stage II or III multiple myeloma treated with bevacizumab, lenalidomide, and dexamethasone. SECONDARY OBJECTIVES: I. Determine time to progression in these patients. II. Determine the toxicity and tolerability of this regimen. III. Determine the effect of bevacizumab and lenalidomide on markers of myeloma activity in myeloma cells and stromal cells, including interleukin-6, macrophage inflammatory protein-1α, vascular endothelial growth factor, and STAT3. IV. Assess local cytokine milieu using tissue microarrays of bone marrow biopsy specimens. OUTLINE: This is a multicenter, open-label study. Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and before courses 2 and 4. Blood samples are examined for vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) polymorphisms by pyrosequencing and VEGF, VEGFR1, VEGFR2, interleukin-6, and macrophage inflammatory protein 1 by immunoenzyme techniques. Relationships between plasma cell myeloma and stroma and the effect of study treatment on these relationships are examined in tissue sections of bone marrow before and after treatment utilizing microvessel density measurements, VEGF staining, and STAT3 staining (by immunohistochemistry and fluorescent in situ hybridization \[FISH\]). After completion of study treatment, patients are followed periodically for at least 5 years.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-b962e7f36abe75c35850
requested nct id
NCT00410605
primary nct id
NCT00410605
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
285d1aba7c7b013c128809d5ea8d15e4a8f0ff988201a66e41aeab1a1286426d
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-b962e7f36abe75c35850
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00410605
occurrences
context exact
NCT00410605
end
11
exact text
NCT00410605
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/120/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
77ab61c78fd7a6120179d9cd952044dbb6948f7524fb26e45f285968723b2a86
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice